AstraZeneca-Oxford Covid Vaccine Has ‘Winning Formula’ : Chief Executive

London : The Covid-19 vaccine developed by the British drugs group AstraZeneca and the University of Oxford has achieved a “winning formula” for efficacy, the company’s chief executive said on Sunday.

The vaccine, currently being evaluated by Britain’s independent medicines regulator, provides “100 percent protection” against severe Covid disease requiring hospitalization, Pascal Soriot said in an interview with the Sunday Times newspaper.

He added he believes trials will show his firm has achieved a vaccine efficacy equal to Pzer-BioNTech at 95 percent and Moderna at 94.5 percent.

“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” the chief executive said, while saying only that data would be published at “some point”.

The UK government announced on December 23 that the developers of the Oxford-AstraZeneca vaccine had submitted their data to the Medicines and Healthcare products Regulatory Agency (MHRA).

Approval is expected to be granted Monday to roll out the jab, The Sunday Telegraph newspaper reported.

Related Posts

  • Pharma
  • July 10, 2025
  • 115 views
Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

  • Pharma
  • July 10, 2025
  • 100 views
Novartis wins approval for first malaria drug for newborns and babies

ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr